Key Drivers
- Strong cash flow
- Rising leverage
- Intangible-heavy assets
AIAI Summary
AMPH now looks like a cash-generating specialty pharma turnaround rather than a generic-drug value trap, but the stock is only investable if newer launches keep growing fast enough to offset legacy erosion while the securities/FDA overhangs are resolved.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •Rising leverage
- •Intangible-heavy assets
AMPH looks financially solid overall, with strong margins and cash generation, but investors should watch rising leverage, softer liquidity, and heavy intangible asset reliance.
Price Behavior
Key Price Behavior Insights:
- •Rebound support
- •Near-term consolidation
- •Breakout needed
AMPH has improved over the last month into a modest uptrend, holding above $20.00 and rebounding from $18.72, but it still needs to clear $20.80-$21.00 and $21.78 to confirm a stronger breakout.
Rebounded sharply from the $18.72 low into a modest uptrend
Sentiment & News
Key News Insights:
- •Revenue growth
- •Product launches
- •Compliance risk
Amphastar delivered solid Q2 2026 results with $183.9M revenue and $0.91 adjusted EPS, helped by new launches, but FDA compliance issues and a bearish Zacks downgrade weigh on the outlook.
The quarter supports near-term momentum, but regulatory and policy headwinds could limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings